Type 2 Diabetes

Announced on January 23, the US FDA's approval of bexagliflozin (Brenzavvy) was awarded to TheracosBio and indicates the SGLT2 inhibitor for use as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

In their final episode from the ADCES 2nd Annual Diabetes Technology Conference, our hosts are joined by Gary Scheiner, MS, and Jennifer Okemah, RD, to discuss their businesses, a glimpse into their personal journeys into becoming diabetes care and education specialists, and how they have seen their role in improving care transform in recent years.

An analysis of patient data from the REGARDS cohort suggests the increase in relative risk observed with traditional risk factors, such as hypertension and diabetes, on risk of stroke decreases as patients age, but investigators point out this does not diminish the importance of addressing these risk factors.

The uptake of modern glucose-monitoring technologies for people with T1D and T2D may be dependent on out-of-pocket costs, suggesting the need to reconsider cost-benefit profiles of these devices.

A higher exposure to both foods and water-originated and additives-originated nitrites was associated with higher T2D risk, showing no potential benefits of their use.

The 2022 updated guidelines includes 13 recommendations and 52 practice points for clinicians caring for patients with diabetes and chronic kidney disease.

An analysis of a commercial claims database offers insight into the increase in vision-threatening eye disease among people with diabetes aged younger than 65 years from 2009-2018, with results also detailing trends in anti-VEGF therapy during the same period.

In this episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, are joined by Steven Russell, MD, PhD, the chief medical officer of Beta Bionics, for a discussion around his journey to becoming CMO as well as a deep dive into the iLet Bionic Pancreas and its potential in diabetes management.

A study examining associations between coffee metabolites and risk of NAFLD severity suggests people with type 2 diabetes had a lower risk of fibrosis and more severe NAFLD based on increased coffee consumption.

Announced by Novo Nordisk on January 12, the label update from the FDA removes a previous indication stating oral semaglutide (Rybelsus) should not be used as an initial therapy, which clears the way for the agent to be used as a first-line therapy in type 2 diabetes.

Higher preoperative visual acuity in patients with dTRD was associated with higher vision after PPV, suggesting the importance of early intervention.

Kimberly Simmons, MD, provides resources for patients with T1D, and key takeaways for pediatricians screening for and diagnosing T1D in pediatric patients.

Tina Q. Tan, MD, and Kimberly Simmons, MD, discuss improved methods of monitoring blood glucose levels in patients with type 1 diabetes.

Using data from the SEARCH for Diabetes in Youth study, a new analysis suggests rates of type 1 diabetes in youth may increase by 65% between now and 2060, while rates of type 2 diabetes could increase more than 600% during that same period if left unchecked.

Results from the REGARDS study suggest traditional CKD risk factors were associated with higher risk of incident CKD and eGFR decline in Black individuals, compared to White individuals.

Eight studies provided evidence to suggest the relationship between diabetes and the onset of frozen shoulder, but more high-quality cohort studies may be necessary to better understand the nature of the relationship.

MAFLD-lean and MAFLD-diabetes subgroups recorded a higher risk of all-cause and disease-specific mortality compared to the MAFLD-overweight/obese group.

Using data from 18 trials with more than 1400 participants, a systematic review and meta-analysis offer clinicians an overview of the effects of SGLT2 inhibitor use on body composition in people with type 2 diabetes.

Using data from more than 55,000 people with diabetes using metformin is providing new insight into the apparent reductions in risk of negative cardiovascular and renal outcomes as well as all-cause mortality with use of SGLT2 inhibitors.

Kimberly Simmons, MD, reviews a new drug in the pipeline for the treatment of pediatric type 1 diabetes.

Experts consider how often a patient with a family history of type 1 diabetes needs to be retested.

Exploratory analyses of data from the Look AHEAD trial suggest maintaining an HbA1c level of 7% or less was associated with smaller increases in frailty index over the 8-year study period when compared to their counterparts with an HbA1c level of 8% or greater.

Drs Diana Isaacs and Natalie Bellini share takeaways for clinicians exploring non-invasive insulin delivery methods to manage diabetes.

Expert healthcare practitioners discuss ongoing studies of inhaled insulin in T2D and how it might fit into treatment protocol.

To celebrate the end of 2022 and the advances witnessed in the past year, our editorial team has created a list of the top 8 most popular pieces of content related to endocrinology from 2022.